Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity
Journal Français d'Ophtalmologie · 2025
DOI: 10.1016/j.jfo.2024.104348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal Français d'Ophtalmologie, 2025. Verfasst von N Sahinoglu-Keskek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Baskent University Faculty of Medicine, Dadaloglu district, 2591, street, 4/A, Adana, 01250 Yuregir, Turkey. Electronic …. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Ranibizumab, Angiogenesis Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Anti-VEGF agents are used in the treatment of aggressive retinopathy of prematurity (A-ROP), which is a rapidly progressive form of retinopathy of prematurity (ROP). This study aimed to evaluate risk factors for the early reactivation after anti-VEGF therapy with intravitreal ranibizumab (IVR) injection. METHODS: Consecutive cases of A-ROP were included in this retrospective study. Intravitreal ranibizumab (0.25mg, Lucentis, Novartis AG) was injected in all A-ROP cases as initial therapy. Probable risk factors were reviewed. A reactivation in 4 weeks or less was defined as "early", and greater than 4 weeks was defined as "late". Since reactivations were observed in Zone II in all cases, laser photocoagulation (LP) was performed as rescue therapy. RESULTS: The study consisted of 16 patients with A-ROP, all of whom experienced reactivation. In 6 cases,reactivation was seen early (Group-E), and in 10 cases, reactivation was late (Group-L). The mean gestational age of Group-E and Group-L were 26.60 (±0.89) and 26.73 (±2.10) weeks respectively (P=0.9), and mean birth weights were 918 (±282) and 898 (±0188) grams respectively (P=0.8). Zone I ROP was seen at a higher rate in Group-E (83.3%) than Group-L (30%) (P=0.009). Total O2 treatment duration in Group-E was statistically significantly longer than Group-L (P=0.03). The mean value of platelet distribution width (PDW) in Group-E was statistically significantly higher (P=0.002). CONCLUSIONS: In patients with A-ROP, extended duration of O2 therapy and high values of PDW might be factors predictive of early reactivation after intravitreal ranibizumab injection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Baskent University Faculty of Medicine, Dadaloglu district, 2591, street, 4/A, Adana, 01250 Yuregir, Turkey. Electronic address: nedime_sahin@yahoo.com.
- Department of Ophthalmology, Baskent University Faculty of Medicine, Dadaloglu district, 2591, street, 4/A, Adana, 01250 Yuregir, Turkey; Department of Ophthalmology, Baskent University Faculty of Medicine, Ankara, Turk…
- Division of Neonatology, Department of Paediatrics, Baskent University Faculty of Medicine, Adana, Turkey; Department of Ophthalmology, Baskent University Faculty of Medicine, Ankara, Turkey.
- Division of Neonatology, Department of Paediatrics, Baskent University Faculty of Medicine, Adana, Turkey.
- Department of Ophthalmology, Baskent University Faculty of Medicine, Dadaloglu district, 2591, street, 4/A, Adana, 01250 Yuregir, Turkey.
Zitieren
APA
Sahinoglu-Keskek, N., Akkoyun, I., Torer, B., Cetinkaya, B., Gülcan, H., Yilmaz, G., & Oto, S. (2025). Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity. Journal Français d'Ophtalmologie. https://doi.org/10.1016/j.jfo.2024.104348
Vancouver
Sahinoglu-Keskek N, Akkoyun I, Torer B, Cetinkaya B, Gülcan H, Yilmaz G, et al. Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity. Journal Français d'Ophtalmologie. 2025. doi:10.1016/j.jfo.2024.104348
BibTeX
@article{SahinogluKeskek2025,
author = {Sahinoglu-Keskek, N and Akkoyun, I and Torer, B and Cetinkaya, B and Gülcan, H and Yilmaz, G and Oto, S},
title = {Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity},
journal = {Journal Français d'Ophtalmologie},
year = {2025},
doi = {10.1016/j.jfo.2024.104348}
}
EUVIMED